The Moderna logo is seen at the Moderna campus in Norwood, Massachusetts
on Thursday reported fourth quarter revenues of $7.2 billion, and diluted earnings of $11.29 per share.
The reported earnings were above FactSet consensus estimates of $6.8 billion of quarterly revenue, and earnings of $9.96 per share.
The company said it has signed advanced purchase agreements for its Covid-19 vaccine, worth $19 billion for 2022, up from the $18.5 billion it had disclosed in early January, and said that “numerous discussions” for late 2022 and 2023 were still ongoing with governments.
The company said it had received orders for 2023 from four countries so far.
Moderna (ticker: MRNA) also announced a $3 billion share repurchase plan.
Moderna shares were down 1.3% in premarket trading on Thursday, as S&P 500 futures fell 2.1%. Moderna shares are down 46.6% so far this year.
Write to Josh Nathan-Kazis at email@example.com